Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
32 results
D2.282 - Impact of Polyethylene Terephthalate Microplastics on the Digestibility of Shrimp Allergen Tropomyosin
D2.283 - Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study
D2.286 - High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients
D2.287 - Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population
D2.275 - Distinct Transcriptomic Responses Across Intestinal Segments in Egg Allergy Murine Model
D2.276 - Clinical and Immunological Differences in Shellfish Allergy
D2.277 - Allergy to CHIA and Reactivity with SESAME
D2.278 - Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy
D2.279 - Preventive capacity of single-nut sublingual immunotherapy in Brown Norway rats
D2.280 - Biphasic anaphylaxis due to psyllium (Plantago ovata) allergy, the primary component of a plant-based sausage
D2.281 - Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in Nigella sativa Seeds and Oil
D2.284 - Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles
D2.285 - Baked egg oral Immunotherapy as an alternative in patients who failed raw egg oral immunotherapy
D2.288 - Real- World Safety of Supervised Feeds: Evidence from Outpatient Clinic and Dayward Settings
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download